Category Archives: Pot Stocks

Get Ready for Cannabis 2.0

ne year ago, on October 17, 2018, Canada legalized marijuana for recreational use.

But that was only the first step.

Now we’re at “Cannabis 2.0.” This comes exactly one year later, on October 17, 2019. Cannabis 2.0 is when Canada will legalize edibles, drinks, vapes, plus a few other categories.

The idea with the Canadian plan was to go about legalization in steps.

The first step of legalization, Cannabis 1.0, unleashed a “green rush” as shares of cannabis stocks soared. The business of getting high was making new highs nearly every day.

Frankly, it got out of hand. The rally soon went bust, and many marijuana stocks tumbled back to earth. Shares of Tilray (TLRY), to use one example, went from $20 to $300.

Then back to $20.

So now that Cannabis 2.0 is here, will we see another explosive rally? My first bit of advice is to slow down. The Canadian law means that on October 17, companies are allowed to file a notice with the government that in 60 days, they’re going to bring new products to the market. (Funny how legalization means bureaucracy and red tape.) So it won’t be until December that anyone can buy anything.

Let’s consider some numbers. Deloitte estimates that the annual market for edibles and alternative cannabis products is worth C$2.7 billion. Of that C2.7 billion, C$1.6 billion is just for edibles, and remember, this is only for Canada.

The key here is breaking down the market. The first wave of legalization was happy news for regular users of marijuana, but the unknown factor is how many occasional users there are.

In addition to that, there could more consumers who have never tried marijuana before due to its illegal status but might be lured in now that it’s legal. There’s been a lot of debate about these so-called “curious” users.

For these folks, they probably want to take baby steps first, and that’s why the edibles legalization is so important. For a person who never inhaled (and watched all their friends get stoned in college), trying a gummi bear might be an easy first step.

So what companies are poised to benefit from Cannabis 2.0? At the top of the list, I’d have to put Canopy Growth (NYSE: CGC). In many ways, this may be the most impressive marijuana stock.

For starters, the company has an NYSE listing. This is important because many institutional investors may shy away from OTC stocks.

I also like that Canopy’s Tweed brand is closely associated with Snoop Dogg, which is a nice relationship to have.

Canopy also has its eye on the future. The company recently made an interesting deal. Canopy offered to buy Acreage Holding (OTC: ACRGF) for $3.4 billion, but there’s a hitch. The deal won’t close until the U.S. legalizes cannabis for recreational use. The deal has a 90-month window, so all bets are off if legalization doesn’t happen. That’s a smart move.

But the most important reason why I like Canopy, and which brings us back to Cannabis 2.0, is that Canopy has developed a close relationship with Constellation Brands (NYSE: STZ). Constellation bought a $4 billion chunk of Canopy stock. This relationship is in the interest of both companies.

Constellation, if you’re not familiar, is a beer and spirits company with a global reach. The company has 9,000 employees and a market cap of $37 billion. Now that cannabis drinks are legal in Canada, it’s nice to have the maker of Corona and Modelo on your side.

This is the perfect partner to have in an effort to reach out to those “curious” consumers. The blue-chip firm could come in handy if Canopy needs to raise a lot of money. The relationship is so close that Canopy recently made the CFO of Constellation Brands its new chairman.

Currently, Canopy has ten production facilities in Canada. That works out to 4.3 million square feet of growing space. Canopy plans to add another 1.3 million square feet. The company also has a hemp production facility in New York state (hemp is legal at the federal level).

This is a good time to give Canopy a close look because the stock was down over the past few months. During the spring, CGC got as high as $52 per share. Lately, it’s been going for less than $20 a piece. That probably cleared out a lot of short-term traders. Cannabis 2.0 could be a major boost for Canopy Growth.

Pay Your Bills for LIFE with These Dividend Stocks

Get your hands on my most comprehensive, step-by-step dividend plan yet. In just a few minutes, you will have a 36-month road map that could generate $4,804 (or more!) per month for life. It's the perfect supplement to Social Security and works even if the stock market tanks. Over 6,500 retirement investors have already followed the recommendations I've laid out.

Click here for complete details to start your plan today.

Source: Investors Alley

The ‘Secret’ Ingredient Set to Send Marijuana Stocks Soaring

Call it the secret ingredient that compels a stock to move higher. It’s like an unstoppable magnetic force that pulls stocks up.

marijuana stocks

Source: Shutterstock

It really shouldn’t be a secret. It’s discussed in every company analysis and every Finance 101 class. It’s available for everyone to see for every publicly traded company.

And yet, investors look right past it, especially in early stage companies and industries when the stocks and numbers tend to be more volatile.

This not-so-secret, secret ingredient is sales. Or revenue, as it’s called on the balance sheet.

The more a company brings in, the more upside potential for a stock.

Here’s the deal: Marijuana companies are right now hitting the investing sweet spot where they are starting to generate significant revenue — yet stock prices are still down.

That makes NOW the time to buy.

A Proven Path to Big Profits

When we look back on 2019, I think we’ll clearly see it was one of the best buying opportunities ever in marijuana stocks. Prices are down even as legalization spreads and sales jump. Eye-popping long-term growth is in the cards, but investors aren’t focused there yet.

History shows the massive profits you can earn. Take a look at both Netflix(NASDAQ:NFLX) and Amazon (NASDAQ:AMZN) and some of the mouth-watering opportunities along their growth paths.This is the chance to buy big growth at low prices.

Netflix & Amazon Chart

Now let’s look at a few marijuana stocks so you can see how they are in that same early stage sweet spot.

Acreage Holdings (OTCMKTS:ACRGF) is a big name in the cannabis industry. Its board includes three of the most connected people on the planet: former U.S. Speaker of the House John Boehner, former Massachusetts Governor and current U.S. presidential candidate William Weld, and former Prime Minister of Canada Brian Mulroney. The company is also central to perhaps the blockbuster marijuana story of the year (so far). Canopy Growth (NYSE:CGC), the biggest cannabis company on the planet, agreed to buy Acreage for $3.4 billion when marijuana becomes legal in the U.S. It was practically a flashing neon sign that U.S. legalization is coming sooner than most expect.

Still, the stock has been cut in half this year despite expectations for revenue to soar more than 3,800%, from $21.1 million in 2018 to $838 million by the end of 2021.

Acreage Holdings Chart

Remember Netflix earlier? If that doesn’t look like a buying opportunity, I don’t know what does.

Harvest Health & Recreation (OTCMKTS:HRVSF) is a lesser-known but equally dramatic example. It has the most retail licenses to open marijuana dispensaries in the U.S., and it has aspirations to be the biggest cannabis company in the world. That’s bold, but the company also has strong management, a solid cash position, and a path to profitability thanks to growing revenue.

Harvest Health Chart

Here again, we have a stock down 50% since April — at a time of exploding revenues … as in from $47 million in 2018 to $1.3 billion by 2022. That 2,665% growth if executed on can be bought for pennies on the dollar.

Now Is The Time

I could show you plenty more similar charts, but I think you get the point. Marijuana stocks are cheap, especially considering the explosive revenue growth that’s anticipated from the biggest players.

Last year, legal marijuana sales in the United States hit $10.4 billion, which is nearly 100% growth over the three-year period going back to 2015. This year, sales should grow nearly 24% to $12.9 billion.

Now just imagine when legal weed is opened up to the entire $21 trillion U.S. economy. We’re talking exponential growth potential in a single stroke.

Marijuana is a massive trend still in its early stages, with the U.S. waiting in the wings to become the biggest market in the world. Any time governments open a huge new market like legal marijuana, investors can win very big. The key is to own the right investments before that happens, and now is the perfect time to start.

Matthew McCall is the founder and president of Penn Financial Group, an investment advisory firm, as well as the editor of Investment Opportunities and Early Stage Investor. He has dedicated his career to getting investors into the world’s biggest, most revolutionary trends BEFORE anyone else. The power of being “first” gave Matt’s readers the chance to bank +2,438% in (STMP), +1,523% in Ulta Beauty (ULTA), +1,044% in Tesla (TSLA), +611% in Liquefied Natural Gas Limited (LNGLY), +324% in Bitcoin Services (BTSC), just to name a few. If you’re interested in making triple-digit gains from the world’s biggest investment trends BEFORE anyone else, 

Pay Your Bills for LIFE with These Dividend Stocks

Get your hands on my most comprehensive, step-by-step dividend plan yet. In just a few minutes, you will have a 36-month road map that could generate $4,804 (or more!) per month for life. It's the perfect supplement to Social Security and works even if the stock market tanks. Over 6,500 retirement investors have already followed the recommendations I've laid out.

Click here for complete details to start your plan today.

Source: Investor Place

4 CBD Stocks to Buy for Mainstream Marijuana Profits

acb stock Aurora Cannabis stock
Source: Shutterstock

[Editor’s note: This story was previously published in March 2019. It has since been updated and republished.]

Traffic stats don’t lie: among investment categories, few have the draw of legal marijuana. And within this broad segment, companies specializing in cannabidiol, or CBD, have generated significant buzz. But what exactly is this three-letter acronym, and how can CBD stocks boost your returns?

Let’s start with basic definitions. Cannabidiol represents one of several cannabinoids, or chemical compounds found in the cannabis sativa plant. But unlike the most famous cannabinoid tetrahydrocannabinol (THC), CBD does not trigger any psychoactive effect. In other words, users can enjoy this compound’s benefits without getting high.

This opens up profound opportunities for marijuana stocks that have exposure to CBD. First, since this compound inherently lends itself to medicinal use, it tends to be treated favorably by legislation. Most states allow CBD use for therapeutic purposes. Given political and public sentiment, it’s not inconceivable that all states will eventually green-light cannabidiol.

Second, CBD has the potential to help solve a huge societal problem. Turn on the news, and you’ll eventually find stories about the raging opioid crisis. What is less reported is that pharmaceutical companies contributed to the problem with highly addictive painkillers. Since CBD is not physically addictive, it could be a viable replacement for many addictive opioids.

Finally, the U.S. may be the leader of the free world, but it stymies itself with antiquated laws. Our neighbors to the north became the first G7 nation to legalize recreational weed, while we still classify cannabis as a Schedule I narcotic. Still, our laws will eventually reach the 21st century. When they do, marijuana stocks of all stripes should realize their full potential.

In the meantime, here are four CBD stocks to consider adding to your portfolio:

Tilray (TLRY)

Marijuana stocks

Source: ShutterstockWhen it comes to medicinal marijuana, few cannabis stocks have generated as much positive traction as Tilray(NASDAQ:TLRY). Last fall, TLRY stock soared to the stratosphere as the underlying firm received approval from the Drug Enforcement Administration to import weed for medical research.

While shares have since come down significantly from those highs, Tilray remains a powerful name among CBD stocks. Recently, management signaled that it will aggressively compete in the cannabidiol sector with its acquisition of Manitoba Harvest. Manitoba specializes in CBD-infused food and health products, providing Tilray a key advantage in the North American market.

From a technical perspective, speculators may want to dive into currently discounted levels. After the crazy phase in marijuana stocks dried up, several names fell under the radar. One of those is TLRY stock, which has mostly moved sideways this year.

But with CBD gaining momentum stateside, who knows how long this discount will last?

Aurora Cannabis (ACB)

Wait for the Next Big Correction to Jump on Canopy Growth Stock

Source: Shutterstock

Much of the enthusiasm towards Edmonton-based CBD (and THC) firm Aurora Cannabis(NYSE:ACB) came off the back of an analyst upgrade. Cowen Equity Research initiated coverage of ACB stock, rating it as “outperform,” and giving it a rich price-target premium.

But it’s also interesting to note why Cowen is so optimistic. Analysts there view favorable international opinion towards marijuana as being beneficial to ACB stock over the long term. It’s not an unreasonable thesis. Among CBD stocks, Aurora has made a significant dent in the global medical-marijuana field.

Plus, the company has a massive market down south. While we’re fiercely divided politically, marijuana legalization is something Americans agree on more than most things.

Hexo (HEXO)

TIlray stock is driven by hype, until it's not

Source: ShutterstockInvariably, marijuana stocks are incredibly risky. While legalization initiatives have opened opportunities, this is a double-edged sword as competitors swarm into the arena. What you’re left with are several companies like Hexo(AMEX:HEXO), which suffer from severely-challenged financials.

But despite the risks, cannabis investors should strongly consider CBD stocks like HEXO. Since cannabidiol doesn’t produce any psychoactive or addictive responses, it facilitates surprisingly broad synergies. A prime example is the budding relationship with marijuana firms and beverage-makers.

Last summer, Hexo entered a joint venture with Molson Coors Brewing(NYSE:TAP) to produce CBD-infused drinks. Naturally, HEXO stock jumped off the news before giving up those gains late last year.

However, shares are making a strong comeback this year, jumping to a 100% lead. While it’s incredibly volatile, further positive developments could easily lift HEXO stock to its prior highs.

BlissCo Cannabis (HSTRF)

cronos stock

Source: ShutterstockI always warn folks that cannabis and CBD stocks are risky because that’s God’s honest truth. But BlissCo Cannabis (OTCMKTS:HSTRF) is an entirely different ballgame. HSTRF stock is so speculative that it makes other companies in this sector look stable.

We can start with the fact that shares currently sell for 29 cents a pop. Unlike some of the established names, the historical trend for HSTRF stock is decidedly negative. Finally, I don’t think I need to say this but BlissCo has severe fiscal challenges.

So why am I mentioning this company? Simple…upside potential. Partnering with both medical professionals and alternative therapists, BlissCo is a known commodity in Canada’s medicinal-cannabis industry.

Year-to-date, shares are up nearly 39%. As BlissCo remains undervalued relative to its historical averages, there’s probably substantial room for growth.

As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities.

Medical Marijuana States See Major Drop in Opioid Prescriptions

Chart - Medical Marijuana States See a Decline in Opioid Prescriptions

In the late 1990s, pharmaceutical companies began promoting prescription opioids as a treatment for pain. Pharmaceutical companies and medical organizations assured doctors that there was a very low risk for addiction. So doctors began prescribing them at higher rates.

Fast-forward to today. Prescription opioids are now known to be dangerously addictive drugs.

According to the latest CDC data, which was collected in 2017, more than 47,000 Americans died that year from opioid overdoses, including prescription opioids. And about 1.7 million Americans suffered from substance use disorders related to prescription opioid pain relievers.

The crisis would likely be worse if it wasn’t for medical marijuana. Medical marijuana, as we’ve reported many times before, has the potential to treat a long list of medical conditions, including pain, epilepsy and others that are often treated with opioids.

By 2017, 29 states had legalized medical marijuana. And that year, nearly every state that legalized medical marijuana saw a decrease in opioid prescription rates from previous years. Today we’re going to look at three states in particular.

Our chart shows the opioid prescription rate per 100 people in New York, Massachusetts and Minnesota in 2010 (pre-medical cannabis legalization) and 2017 (post-legalization). And the difference is stark.

Massachusetts legalized medical marijuana in 2013. From 2010 to 2017, its opioid prescription rate dropped 41%. Minnesota, which legalized medical marijuana in 2014, saw a 31% drop. New York also legalized medical marijuana in 2014. Its opioid prescription rate fell 25%. New York’s 2017 opioid prescription rate was the lowest in the country.

New York has been building on this progress. In 2018, New York lawmakers authorized the use of medical marijuana to treat opioid addiction.

Enlisting medical cannabis in the fight against the opioid crisis is a smart move – not just for patients, but for the government too. Researchers from the University of California San Diego and Weill Cornell Medical College discovered that medical cannabis was associated with a nearly 30% reduction in Schedule III opioids received by Medicaid patients.

“[I]f all the states had legalized medical cannabis by 2014, Medicaid annual spending on opioid prescriptions would be reduced by $17.8 million,” the study projected.

This is why medical cannabis legalization is a no-brainer. Legalization means fewer patients are forced to settle for addictive (and sometimes ineffective) drugs with nasty side effects. More patients are able to turn to cannabis as a safer option. And the government saves millions of dollars.

Medical marijuana is making a difference. The reduction in opioid prescription rates is a sure sign of that.

Good investing,

Allison Brickell

Assistant Managing Editor, Early Investing

A Pizza Company More Profitable Than Amazon?
Forget Tesla, Amazon, Netflix and Google! A Pizza Company has beat every single one of these tech giants... and made its investors over 2,500% since 2010.
It's all thanks to a $100 Trillion ‘Digital Helix’ and it could make YOU 2,537% profits if you act before November 29.
Click here to find out more...

Source: Early Investing

5 Cannabis Stocks Set to Skyrocket — According to Wall Street’s Top Analysts

acb stock Aurora Cannabis stock
Source: Shutterstock

The cannabis market is buzzing right now. According to Cowen & Co’s Vivien Azer — aka the first pot analyst — U.S. marijuana sales are set to reach about $80 billion by 2030. Currently, U.S. legal and illicit sales total at least $50 billion. That’s on top of an estimated 12 billion Canadian dollars in revenue by 2025, for both recreational and medical use, and $31 billion by 2025 in the 43 countries that have legalized medical cannabis or are likely to do so. In short, cannabis stocks represent a very compelling investing opportunity.

But which cannabis stocks are worth your time and money? Because honestly some pot stocks look seriously overvalued. For example Canaccord Genuity just downgraded Cronos Group (NASDAQ:CRON) to ‘Sell’ because ‘valuation has gotten ahead of fundamentals.’ So using TipRanks Top Analysts Stocks tool, I pinpoint five cannabis stocks that still have plenty of upside ahead. I believe that all these stocks make very intriguing investments right now. Let’s take a closer look:

Aphria (APHA)

Source: ShutterstockAphria (NYSE:APHA) sells medical marijuana direct to registered patients across Canada. It was the first Canadian LP to exclusively use greenhouses and is still one of the lowest-cost producers in the Canadian industry.

In the last three years, shares have rocketed by over 700% to $9.32. So despite the extreme gains, this remains a fairly cheap cannabis option. And now Aphria is set to soar higher.

Year-to-date, APHA stock has already surged over 60% as the company turns its back on a disastrous 2018. At the end of last year, Aphria was embroiled in a sticky legal situation, which featured a hostile takeover attempt and the exit of its CEO. Most worryingly, a short-seller alleged that insiders profited from acquiring international businesses at highly inflated prices.

However, a special board committee has now found that the price paid was acceptable and that the assets are progressing according to plan. As a result, top-rated Clarus analyst Noel Atkinson (Track Record & Ratings) has reiterated his buy rating on APHA. That’s with a new price target of $22.75, up from $19.25 previously — suggesting upside potential of over 100%.

Now Aphria needs to get its mojo back by refocusing on key operational items. This includes Health Canada cultivation approvals for Leamington Part IV and the Aphria Diamond facility, EU GMP status for export, and the launch of softgels. Plus the company’s new CEO has extensive executive experience guiding multi-billion-dollar CPG companies.

“Aphria’s list of near-term operational milestones is significant, and successful execution in a timely fashion could transform the Company both in terms of financial results and investor sentiment. If management can execute, there is the potential for a very substantial re-rating of the stock price from current levels” Atkinson tells investors.

Overall the stock earns a ‘Strong Buy’ consensus from the Street. Out of 5 analysts covering the stock, 4 have published bullish ratings. Want to learn more about Aphria Inc? Get the free APHA Stock Research Report.

Zynerba (ZYNE)

zynerba stock syne stock

Source: Zynerba PharmaceuticalsIf you haven’t heard of Zynerba Pharmaceuticals (NASDAQ:ZYNE) before, listen up. This promising biotech is currently running clinical trials for a groundbreaking cannabinoid (CBD) gel. Yes that’s right, gel. This is the first and only patented permeation-enhanced CBD gel for delivery through the skin and into the circulatory system.

According to ZYNE, the gel delivers drugs without using the digestive process. In doing so, it minimizes psychoactive effects, limits drug-drug interaction, and avoids digestion of the drug by the liver. Zynerba wants to use this to help treat rare neuropsychiatric conditions like Fragile X syndrome and autism spectrum disorder.

As far as investing is concerned, the upside potential is jaw dropping. Five-star HC Wainwright analyst Oren Livnat (Track Record & Ratings) reiterated his buy rating on ZYNE with a $23 price target on March 18- indicating 324% upside potential lies ahead.

Livnat noted, “We reiterate our Buy, rating and see the current $105M market cap ($27M EV) leaving remarkable upside potential on positive data; as our $23 price target still reflects only a 35% probability of success in FXS.” So keep an eye out for pivotal data from ZYNE’s lead FXS program, due by 4Q19. “We remain optimistic for positive data” adds the analyst.

Only three Wall Street analysts are covering ZYNE stock right now. But all three are a ‘buy’. With shares trading at just $5.42, their $20 average price target suggests shares have huge upside potential of over 250%. Get the ZYNE Stock Research Report.

Tilray (TLRY)

Wait For Canopy Growth Stock To Fall To $40 Before Longer-Term Uptrend

Source: Shutterstock Tilray Inc (NASDAQ:TLRY) is one of the largest producers of medical cannabis in the world. The company is set to be a major player in the evolving cannabis space, with supply agreements for no less than 8 Canadian provinces for adult use, and medical products currently available in 12 countries worldwide.

In just one-year prices have exploded by 192%– leading to accusations that the stock is ‘ridiculously expensive’. But I disagree, and so does five-star Cowen & Co analyst Vivien Azer (Track Record & Ratings). She is one of the best consumer goods analysts around and has just reiterated a buy rating on the stock with a $150 price target. From current levels that means we are talking about a further 129% upside. In other words, share prices can more than double.

So what will push prices higher? Azer is bullish on Tilray’s new $419 million CAD acquisition, Manitoba Harvest. By snapping up the world’s largest hemp food company, Tilray can ramp up its position in the fast-moving U.S. Cannabidiol market. According to Azer, this should help Tilray stabilize its top line in the face of supply constraints for Canadian recreational weed use. She raised her sales estimate for the current fiscal year to $179.4 million from $119.5 million, while boosting her fiscal 2020 revenue forecast as well. “We continue to believe that TLRY can reach CPG-like margins of ~30% longer-term” the analyst concludes. Get the TLRY Stock Research Report.

Cara Therapeutics (CARA)

gene editing spark stock

Source: ShutterstockFrom one of the world’s largest cannabis companies to one of the smallest. As far as cannabis stocks go, Cara Therapeutics (NASDAQ:CARA) continues to trade relatively under-the-radar. This clinical-stage biotech is busy developing a novel kappa opioid receptor agonist to change the way pain is managed.

Its lead drug candidate Korsuva has so far shown promising pain relief in clinical trials. Excitingly, this is without many of the traditional side effects that you see with mu opioids (morphine, oxycodone and hydrocodone) and NSAIDs (ibuprofen). That includes abuse liability. On top of this the company is developing a synthetic cannabinoid drug as a novel therapeutic approach for neuropathic pain.

“We believe that Cara is positioned to experience a transformational 2019, with the first few waves of major value inflection points that will bring it closer to a commercial stage company” cheers top Cantor Fitzgerald analyst Charles Duncan (Track Record & Ratings). He has just reiterated his CARA buy rating with a $27 price target.

Most notably, the company will reveal critical phase 3 data for chronic kidney disease associated pruritus in 2Q19. With strong results from previous trials, analysts are optimistic that the data will meet its desired targets. And a partnership with Fresenius (worldwide hemodialysis provider) provides further upside potential post-approval.

“We believe that IV KORSUVA will prove to be a commercially de-risked asset should it get approved in the U.S. and EU because of the company’s agreement with Vifor Fresenius Medical Care Renal Pharma,” states Duncan. Indeed, six out of seven analysts are bullish on Cara Therapeutics right now. That gives the stock its ‘Strong Buy’ Street consensus.

Shares are currently trading up 50% year-to-date. Get the CARA Stock Research Report.

Constellation Brands (STZ)

Source: ShutterstockAs we all know Constellation Brands (NYSE:STZ) is a drinks giant, with Corona one of the most popular beer brands under its umbrella. But thanks to its savvy Canopy Growth (NYSE:CGC) investment, STZ also provides unique exposure to the burgeoning cannabis market.

Following a $4 billion investment, STZ now owns a 38% stake in Canopy, one of the world’s largest cannabis companies. Canopy boasts a leading position in both the recreational and medical markets, and is now also aggressively expanding into U.S. hemp production.

“We continue to see compelling upside in STZ as we est. the base biz’s implied valuation has declined to ~12.5x NTM EV/EBITDA vs. its ~15.5x five-yr avg. and ~13.5x for staples, despite STZ’s much stronger financial profile” explains Jefferies analyst Kevin Grundy (Track Record & Ratings).

He calls Constellation his ‘top pick for 2019’. As well as a compelling valuation and weed exposure via Canopy, STZ also boasts continuing strong beer growth and achievable Street margin estimates. With this in mind, Grundy reiterates his buy rating with a $258 price target. From current levels, this means we are looking at substantial upside potential of around 45%.

Interestingly, Grundy adds that even without Canopy he would ascribe STZ a $233 price target. That still indicates 33% upside potential lies ahead. Basically STZ’s investment in Canopy is a free call option in the stock at these current levels. Get the STZ Stock Research Report. offers exclusive insights for investors by focusing on the moves of experts: Analysts, Insiders, Bloggers, Hedge Fund Managers and more. See what the experts are saying about your stocks now at As of this writing, Harriet Lefton did not hold a position in any of the aforementioned securities.

Pay Your Bills for LIFE with These Dividend Stocks

Get your hands on my most comprehensive, step-by-step dividend plan yet. In just a few minutes, you will have a 36-month road map that could generate $4,804 (or more!) per month for life. It's the perfect supplement to Social Security and works even if the stock market tanks. Over 6,500 retirement investors have already followed the recommendations I've laid out.

Click here for complete details to start your plan today.

Source: Investor Place

Tilray Stock Mania Holds Its Breath as Earnings Approach

The social stigma against marijuana continues to slowly dissipate.

Tilray Stock Mania Holds Its Breath as Earnings Approach

Source: Shutterstock

A construction worker’s pick-up truck passed me twice during a recent walk, apparently looking for a job site, the smell of marijuana smoke redolent in the air. It’s still illegal to smoke in Georgia, but that doesn’t mean the illegal market isn’t operating …

But what about the legal market?

Stock in Tilray (NASDAQ:TLRY), the Canadian pot company, now sits finely poised between earnings due on today after the bell and a shortage of stock to short.

Tilray stock is expected to lose 12 cents per share on revenue of $14.15 million. (Earnings Whispers puts the numbers for earnings and revenue at -15 cents and $17.69mm, respectively.) But that may be less important to speculators than Tilray’s efforts to create credibility with the marijuana and general investor communities.

Consider the following: Tilray has appointed Andrew Pucher, a former managing director at Goldman Sachs (NYSE:GS), as chief corporate development officer.

Pucher joins a team that now includes former executives from Nestle (OTCMKTS:NSRGY), Diageo (NYSE:DEO), Coca-Cola (NYSE:KO) and Starbucks (NASDAQ:SBUX). Further, Tilray has a partnership with Novartis (NYSE:NVS), a joint venture with Anheuser-Busch InBev(NYSE:BUD) and a production agreement with the privately-held Authentic Brands Group.

Finally, Tilray last week announced a deal to buy Manitoba Harvest from Compass Group(NYSE:CODI) for about $315 million.

With all this corporate star power and deal-making, you would think Tilray would be a major pot producer.

What About the Product?

What product?

Tilray sold no marijuana during the first two weeks after Canada legalized it in October. CEO Brendan Kennedy insisted that this will have changed by this quarter, while simultaneously announcing he bought producer Natura Naturals for $26.3 million. If all this is leaving you skeptical about the company, you’re not alone …

Tilray short interest recently stood at 4 million shares, 24.62% of the company’s float, and there’s no more available to borrow. That’s why shares of a company that may report revenue of $17 million trade at a market capitalization of almost $7 billion.

The other is that most of the shares don’t trade, with over 78% held by “individual stakeholders.” There are 79 million shares outstanding.

The Marijuana Market

Speculators are betting that over the next few years, many more U.S. states will legalize marijuana sales and are looking to legislators for guidance.

New Jersey is the latest with a bill to allow recreational sales. Meanwhile, Massachusetts is getting a network of pot shops, debate has begun in Connecticut and New York Governor Andrew Cuomo is pushing the issue.

But despite the examples of Colorado and Washington, the path to legal pot is still not a straight line.

Minnesota Republicans recently rejected a legalization effort, prospects are dimming in New Mexico and New York’s move is being held up by black legislators who want specific provisionsfor their communities to benefit.

As a result, most moves lately have been toward legalizing medical marijuana, with doctors’ prescriptions and extensive regulation. Florida is moving in that direction. So is Oklahoma.

All that said, marijuana remains an illegal drug under U.S. law.

People are still being put in jail for marijuana offenses and Tesla (NASDAQ:TSLA) CEO Elon Musk may lose his SpaceX security clearance after being shown on video smoking pot on a podcast.

Bottom Line on Tilray Stock

Despite the success of Colorado, where marijuana sales are now growing at only single-digit rates in the fifth year of legalization, the product remains controversial.

Tilray and its competitors are preparing for an opportunity that may not come to them for years. Meanwhile, marijuana stocks have been bid well beyond fundamentals. A lot of people are cashing big paychecks, and the dream of a well-regulated American pot market remains hazy.

Dana Blankenhorn is a financial and technology journalist. He is the author of a new mystery thriller, The Reluctant Detective Finds Her Family, available now at the Amazon Kindle store. Write him at danablankenhorn@gmail.comor follow him on Twitter at @danablankenhorn. As of this writing, he owned no shares in companies mentioned in this article.

Source: Investor Place

Bank 100% with the Best Marijuana Stock to Buy Today

We’ve been telling you for some time about the top pot stocks to watch.

Today, we’ve got a slightly different story about the best marijuana stock to buy today.

It’s Money Morning Director of Cannabis Investing Research Greg Miller’s top pick.

best marijuana stocks to buy today

It’s Aphria Inc. (NYSE: APHA).

And Greg Miller believes that the share price of the best marijuana stock to buy today has been beaten down by the actions of short sellers. As a result, investors can benefit.

We believe APHA could double investors’ money in 2019.

Here’s why…

Short Selling and How It Works

Traders sell stocks short by borrowing shares from other investors and selling them on the market. Short sellers hope that they can buy back shares at a reduced price when it’s time to give back shares to the folks they borrowed them from. They then return the borrowed shares at a lower price and make a profit from the price differential between when they borrowed and when they returned.

But if the prices of the shares they’ve borrowed actually rise, short sellers stand to lose money. In fact, they can lose an infinite amount of money, since the share price could theoretically climb continually.

So Miller says that sometimes short sellers take matters into their own hands. They publicize that a company is riddled with problems via articles and television appearances, for instance. If investors are then convinced to sell the stock, the price is more likely to decline. And that’s good news for short sellers.

But if a company targeted by short sellers is in fact in good shape, knowledgeable traders can make money by doing the opposite of the short sellers.

Take the example of Herbalife Ltd. (NYSE: HLF) back in 2014. HLF shares were hit hard when Bill Ackman, a prominent hedge fund manager, took a billion-dollar short position on HLF.

He took to TV, print, and even conferences to tell investors Herbalife was a doomed company. But his gambit failed when investors weren’t fooled. Ultimately, Ackman had to abandon his position at a massive loss.

In the past year, HLF has risen 67%. Revenue climbed 7.7%. Its EBITA rose 4%, and its free cash flow at a 1.2% rate. The company enjoys cash of $1.28 billion and has debt of $2.17 billion.

It’s a strong company financially, so Ackman’s war was ultimately defeated by business growth and good financials.

We believe that Aphria is in a similar situation now.

Why Aphria Is the Best Marijuana Stock to Buy Today

Short sellers are currently alleging that Aphria made illegal transactions in overseas markets, including Colombia, Argentina, and Jamaica.

Aphria didn’t respond quickly enough, and the shares took a hit. But because we believe there is scant substance to the claims, the shares are currently undervalued.

Aphria shares fell a huge 70% between Sept. 12, 2018, and its low point. In fact, after research firms Quintessential Capital Management and Hindenburg Research questioned its Latin American acquisitions in early December, the stock dropped 23% in a single day.

The stock’s trading was halted the day after.

Aphria management, however, said it’s committed to its acquisitions. Then, it purchased over $3.1 million of APHA – a vote of management confidence.

Purchases like that by company insiders is a testimony to what the company’s actual financial position and growth prospects are.

Miller points out that the allegations about Aphria don’t really hold up. One of the allegations, for example, is that the company’s cash flow is negative. But that’s a common issue among both companies engaged in marijuana and in startups. They are still in the development stage.

Other allegations center around product quality. But Miller observes that the company’s business model is mass-market consumers, not high-end. In fact, it’s analogous to Anheuser-Busch InBev S.A. (NYSE: BUD), the company that produces Budweiser. Plenty of money can be made producing products for the bulk of people, not for the artisanal crowd.

Neither of these reasons is compelling, in Miller’s view.

But the short sellers’ final argument is really the worst. And it could be the impetus to double investors’ money in the best marijuana stock to buy today.

The Last Allegation

Short sellers are also claiming that Aphria overpaid for assets because insiders wanted the money.

Miller doesn’t believe that claim. He says that the chief executive officer of Aphria, Vic Neufeld, is also on the board of directions of SOL Global Holdings. SOL is a company that did sell assets to Aphria. But a CEO sitting on another board is extremely common. Neufeld’s holdings in SOL were under 2%.

He therefore wouldn’t profit much for the risk of impropriety. Without firm evidence, the claim can’t be substantiated.

But there’s good news coming out of this. APHA retained Clarus Securities Inc.for an independent appraisal and fairness opinion. Clarus is a highly important investment bank that works with the Canadian marijuana sector.

Miller believes the allegations are hot air that can’t hold up. But the damage inflicted on the stock does create a buying opportunity for investors.

Aphria is one of the best five marijuana firms in Canada. Given the importance of the Canadian market, that means it’s one of the top cannabis companies today.

The stock currently trades near lows it hasn’t seen in 15 months. It also has a past pattern of huge swings in price. Both position investors to make a profit in the best marijuana stock to buy today.

Aphria is approved by Health Canada, which is very important in its market. Its agreements for distribution throughout Canada still stand. And our neighbor to the north doesn’t have enough marijuana to meet demand in the wake of the 2018 legalization.

Company management has faith in Aphria, as witnessed by management buying more shares.

We believe this is a compelling company at a compelling price.

Even if APHA just returns to its November 2018 levels, which were under the high for last year, investors could realize a 100% profit on the stock.

Source: Money Morning News Team

Will Aurora Cannabis Be Next to Secure a Big Partnership?

There’s a rush for companies to get exposure to the cannabis industry and it has left many wondering what company will be next. Will it be Aurora Cannabis (NYSE:ACB) and its $5.3 billion market cap?

At that valuation, that’s smaller than some of the more well-known players like Tilray(NASDAQ:TLRY) and Canopy Growth (NYSE:CGC), but larger than Cronos Group(NASDAQ:CRON) and New Age Beverages (NASDAQ:NBEV). Following a string of partnership and equity stakes, it’s unlikely that the deals are going to stop. With the cannabis space growing rapidly, there’s no reason for larger companies seeking growth to ignore the space.

In fact, it’s a match made in heaven. Many of these companies — ranging from pharmaceutical to alcohol and tobacco companies — already have experience navigating a sea of regulations. They also have the financial muscle to leverage these opportunities, as well as the distribution network in place to take advantage of it.

Is a Deal Next for Aurora?

Canopy Growth received a $4 billion investment from Constellation Brands (NYSE:STZ) and Altria (NYSE:MO) sunk $1.8 billion into Cronos. Tilray grabbed a deal with Sandoz, a unit of Novartis (NYSE:NVS), and also locked into a $100 million partnership with Anheuser-Busch(NYSE:BUD).

To think that the deals will stop there is crazy. Obviously we don’t know who will step in next, when they’ll do it or which cannabis partner they’ll select. But at some point, I wouldn’t be surprised to see ACB have its name called.

The tough part here becomes valuation and momentum. Think if alcohol were illegal, but the world (and more specifically the U.S.) were trending toward legalization. We would want a piece of the action, right? Names like Bud, Molson (NYSE:TAP), Diageo (NYSE:DEO), etc., would come to mind. But if everyone had the same thought and started buying ahead, would it still be worthwhile to get in, particularly as other big-name companies — say PepsiCo (NYSE:PEP) and Coca-Cola (NYSE:KO) for instance — were doing it too?

Depending on one’s time frame, then yes, it’s probably advantageous. But no one wants to hold onto a dead-money investment for years on end. So we have to try to balance these companies’ current valuation with their future opportunities.

Trading ACB and Valuing Its Growth

Aurora is experiencing strong growth. In the fourth quarter of 2018, sales came in at $19.1 million. In Q1 2019, sales ballooned 55% quarter-over-quarter to $29.7 million and grew 260% year-over-year. Put simply, the growth for ACB stock and many other cannabis companies is simply astronomical. It’s a gold rush, if you will.

That said, expenses are growing quickly too. Production jumped more than 100% year-over-year, while operating costs of $119.9 million last quarter were vastly higher than the $10.2 million in Q1 2018. While gross margins of 70% were down from the 74% in Q4, it’s up significantly from the 58% in Q1. That’s likely as larger volumes and more efficiencies drive stronger bottom-line results.

Still, I understand investors’ hesitancy to get long a name at a $5+ billion market cap when it has $30 million in quarterly sales. Certainly ACB and others are not for everyone and I would only consider it a speculative position. That said, cannabis acceptance is only gaining momentum over time and that’s likely to remain the case going forward.

chart of ACB stock price

What do the charts look like?

Unfortunately, unlike the cannabis movement, ACB stock is not gaining momentum. I would like to see ACB get back over $5.50, clearing level support (black line) downtrend resistance (purple line) and the 21-day moving average.

Investors who want a low-risk entry opportunity can buy on a test of uptrend support (blue line), but right now, I need the technicals to play ball. If not, getting bullish is too hard in this environment given the high valuation.

A Pizza Company More Profitable Than Amazon?
Forget Tesla, Amazon, Netflix and Google! A Pizza Company has beat every single one of these tech giants... and made its investors over 2,500% since 2010.
It's all thanks to a $100 Trillion ‘Digital Helix’ and it could make YOU 2,537% profits if you act before November 29.
Click here to find out more...

Source: Investor Place 

Canopy Growth Stock And Its Sister Company Are Both Attractive

marijuana stock

Source: Shutterstock

There’s no doubt that Canopy Growth (NYSE:CGC), stock is one of the best bets among Canadian cannabis companies, thanks in large part to the substantial financial support that the company is getting from Constellation Brands (NYSE:STZ).

In July, I suggested that interested investors hedge their bets on Canopy Growth stock by buying equivalent amounts of CGC stock and Constellation stock.

The Bigger Picture

If you feel strongly about the marijuana industry’s future growth, the smart move would be to take the amount you are prepared to lose on Canopy Growth and cut it (in) half, putting 50% into CGC stock and the other 50% into Constellation Brands,” I wrote on Jul. 5.

“Long-term, I think you’ll be pleased with your decision to hedge your bet.”

A $10,000 bet on CGC stock made on Jul. 5 earned $221 through December 14. A 50/50 split between CGC stock and Constellation lost $688 due to a 16% decline in STZ stock over the last five months; analysts have become wary of Constellation’s $4 billion investment in Canopy.

“Branding will be key to unlocking value in cannabis business, but the winners are far from clear,” said Macquarie analyst Caroline Levy in November. “It thus seems difficult to see any near-term profits for Canopy and possibly sub-par returns for many years, if it continues to prioritize sales growth and market share.”

That is precisely why I recommended that investors hedge their bet in the first place. If Canopy Growth stock doesn’t fly, Constellation will take a hit in the short-term, but over the long-term, STZ will be fine.

If you put all your eggs in one basket, you could end up with a big goose egg.

Another option, which I’ve suggested before, is to buy a cannabis ETF like ETFMG Alternative Harvest ETF (NYSEARCA:MJ). ETFs spread the risk beyond CGC stock.

An Option for Risk-Tolerant Investors

Unless you follow Canopy Growth stock closely, you’ve likely never heard of Canopy Rivers (OTCMKTS:CNPOF), a Toronto-based venture capital investment firm. Canopy Rivers makes investments in best-in-class private and publicly-traded companies across the cannabis value chain, from producers to marketers and everything in between.

CGC owns approximately 25% of Canopy Rivers’ stock. Bruce Linton, the co-founder and CEO of Canopy Growth, is acting CEO of Canopy Rivers. 

Canopy Growth’s consulting firm, XIB Consulting Inc, provides deal flow to Canopy Rivers. The two principals of XIB, Sean McNulty and Peter Hatziioannou, own shares in Canopy Rivers

“We decided to create a separate vehicle where we would could take minority interests, create alternative transaction structures and provide both growth capital and strategic support,” McNulty said about Canopy Rivers in November.“The deal flow is sometimes overwhelming. We’ve evaluated hundreds and hundreds of opportunities, but we’re very picky because we’re trying to get it right for every investment.”

So far, XIB has found 11 investment opportunities for Canopy Rivers. If the U.S. federal government legalizes pot, which most expect will happen sooner rather than later, McNulty and Hatziioannou will have to hire more professionals to carry out due diligence.

That would be a great problem to have.

The Bottom Line on CGC Stock

I believe the CGC-Constellation tie-up is a good one for both companies’ shareholders.

As for Canopy Rivers, if you’re more risk-tolerant, the shares provide a compelling investment opportunity after losing 57% of their value since their public debut on Sept. 20.

However, I wouldn’t use a retirement investment vehicle to buy CGC stock because you won’t be able to deduct any capital losses from your taxes.

As of this writing Will Ashworth did not hold a position in any of the aforementioned securities.

Buffett just went all-in on THIS new asset. Will you?
Buffett could see this new asset run 2,524% in 2018. And he's not the only one... Mark Cuban says "it's the most exciting thing I've ever seen." Mark Zuckerberg threw down $19 billion to get a piece... Bill Gates wagered $26 billion trying to control it...
What is it?
It's not gold, crypto or any mainstream investment. But these mega-billionaires have bet the farm it's about to be the most valuable asset on Earth. Wall Street and the financial media have no clue what's about to happen...And if you act fast, you could earn as much as 2,524% before the year is up.
Click here to find out what it is.

Source: Investor Place

The 10 Best Marijuana Stocks to Buy in 2019

Any cursory look at the markets would reveal that 2018 wasn’t the best year for investors. That goes for speculative assets as well, including marijuana stocks. Although going green has proven net positive for the early birds, the sector tanked heavily during the October selloff. Still, I wouldn’t drop them from your list of stocks to buy just yet.

Despite their well-publicized fall from grace, several marijuana stocks have stabilized from their severe correction. While that’s no guarantee that the industry is done spilling blood, the deflated prices will almost certainly attract speculators. Should enough risk-takers enter the arena, publicly traded cannabis companies will jump higher, even if it’s only a temporary swing.

However, some other factors suggest that marijuana stocks may enjoy a sustained rise. First, none of the big waves currently spooking benchmark indices affect the legal cannabis industry. Whether it’s political unrest in the Middle East, the spiraling protests in Paris or the ugly Huawei controversy, marijuana for now is mostly a North American issue.

Second, medical cannabis potentially offers significant social utility. A stunning Bloomberg article analyzed whether Gilead Sciences (NASDAQ:GILD) made the right business decision in producing a drug that cured diseases rather than managing them. The perception exists that big pharma companies should focus primarily focus on revenue generation rather than medical breakthroughs.

On the other hand, medical marijuana companies have no such quandaries. Because they are typically much smaller outfits, they don’t mind the inability to patent a naturally occurring plant. If anything, an organization that produces a proven, effective cannabis strain would represent a buyout target. This asymmetry challenges big pharma, but makes marijuana-based pharmaceuticals among the best stocks to buy.

While the sector remains risky, the deflated market environment offers attractive deals on these 10 marijuana stocks.

Tilray (TLRY)

Tilray (NASDAQ:TLRY) easily represents the most interesting and controversial picks among marijuana stocks to buy for next year. Within a few months after its initial public offering, TLRY stock pulled a ten-bagger. But as you know, the victory was short-lived, and Tilray came crashing down to earth.

Naturally, several analysts and commentators blasted the company as an unsustainable bubble. Keep in mind, though, that since its IPO, TLRY stock is up over 470%. I wouldn’t dismiss such a performance as a failure. Moreover, shares have stabilized near the $100 level. If this company was as terrible as the bears claimed, I doubt TLRY would ride this support line.

Now, it’s easy to dismiss any individual opinion. It’s much harder when a banking giant like Barclays (NYSE:BCSincreases their position. Clearly, they view TLRY as one of the best stocks to buy in 2019, and they’re putting their money where their mouth is.

Canopy Growth (CGC)

The prior two months have not been for Canopy Growth (NYSE:CGC). Taking a similar route to most other marijuana stocks, CGC dropped 26% in October. The following November appeared promising, building off a sharp burst of momentum. Unfortunately, the rally lost traction and CGC ended up losing double-digits for the month.

But what I like about Canopy Growth is that true to its name, it’s a steady grower. Despite the recent sharp losses, its longer-term bullish trend channel remains intact. I wouldn’t consider hitting the panic button unless shares started to decisively fall below the $25 level. That said, I think the broader fundamentals favor CGC stock.

Tilray has a financial institution backing it. For Canopy Growth, they have alcoholic-beverages maker Constellation Brands (NYSE:STZ). This is a trend that investors, even the skeptical ones, shouldn’t ignore. Big money is increasingly stepping into the cannabis sector, making CGC one of the best stocks to buy despite its well-publicized setbacks.

Cronos Group (CRON)

While most marijuana stocks have struggled to rekindle their prior catalysts, Cronos Group(NASDAQ:CRON) currently stands above the competition. For the month so far, CRON stock has streaked to an amazing 39% lead. Of course, most of that optimism comes courtesy of Altria Group (NYSE:MO).

The iconic tobacco company made headlines when it announced a partnership with Cronos. The deal, worth $1.8 billion, provides CRON with a boatload of cash to further develop its cannabinoid (CBD) products. On the other side of the fence, Altria needs something fresh to reinvigorate its traditional tobacco business.

A key long-term synergy could be the vaporizer market. Vaping CBD e-liquids have taken off in terms of popularity. Altria has attempted to break into the vaporizer market with its own heat-not-burn tobacco products. But with Cronos’ expertise in CBD, Altria has another angle in this sector to work.

In the meantime, feel free to put CRON in your list of best stocks to buy for next year.

Aurora Cannabis (ACB)

Aurora Cannabis (NYSE:ACB) has suffered a disjointed long-term performance in the markets, even compared to other marijuana stocks. In 2017, ACB stock shot from near-obscurity to the toast of Wall Street. This year, ACB has shown flashes of brilliance, but little to show for it overall.

I expect the cannabis sector to wake from its slumber. When it does, the currently embattled ACB has the potential to become one of the best stocks to buy for 2019. The markets really haven’t responded positively to Aurora’s buyout of Farmacias Magistrales. Farmacias made news when it became the first, and so far only Mexican importer of raw materials that contain the psychoactive component THC.

The buyout allows Aurora a viable channel to Latin America’s medical-marijuana market. In addition to Farmacias, ACB has operations in Colombia and Uruguay. Should the industry establish medical breakthroughs in Latin America, advocates will pressure the U.S. to further loosen federal cannabis restrictions.

Auxly Cannabis (CBWTF)

One of the most common misconceptions is that legal-cannabis advocates are only “fronting” to get high. While that use is unavoidable, the botanical industry has several legitimate applications. On the business aspect, several investors assume that all cannabis companies focus on growing weed.

But as Auxly Cannabis (OTCMKTS:CBWTF) demonstrates, marijuana stocks feature the same vibrancy and dynamism as other commodity related investments. Auxly specializes in all areas of the legal-cannabis supply chain, with a primary focus on upstream operations. This involves partnering with companies that grow the actual product.

In addition, CBWTF levers a viable midstream operation. This includes activities such as extraction, processing and branding. It also involves longer-term efforts like research and development.

The biggest advantage for CBWTF to pull this streaming business off is its balance sheet. With a favorable cash-to-debt ratio, Auxly can make key acquisitions and investments while the cannabis market is still young.

Origin House (ORHOF)

Formerly known as CannaRoyalty, Origin House (OTCMKTS:ORHOF) is another cannabis firm that made its name through streaming businesses. And while it still generates some revenue through its initial line of work, ORHOF has become a powerhouse in branding.

The proof is in its utter domination of California. Unbeknownst to me prior to this write-up, the Golden State is the world’s largest legal cannabis market. With a title like that, it’s a wonder how anything gets done around here. Joking aside, Origin House boasts more than 450 California-based dispensaries and more than 50 popular brands.

In other words, if you can make it in California, you can make it anywhere. This bodes very well for ORHOF stock. Last month’s midterm elections proved that legal weed is gaining serious momentum. Inevitably, more recreational markets will open, allowing Origin House to expand its dominating presence.

Marimed (MRMD)

Let’s face facts: Marijuana stocks don’t exactly have the greatest reputation for stability. That goes five-fold for over-the-counter offerings. One notable exception to this rule is Marimed(OTCMKTS:MRMD).

While other sector players hemorrhaged severely during the October rout, MRMD stock actually enjoyed a standout performance, gaining nearly 19%. That said, Marimed eventually gave up those gains and then some. Since the first of November, MRMD is down a little over 17%.

Still, I think it’s fair to say that compared against other marijuana stocks to buy, Marimed has held up well. Heading into the new year, MRMD has the potential to turn heads.

Its biggest advantage is its highly demanded consultation services. Covering everything from licensing application support to facilities management, MRMD provides relevant and critical insights for budding entrepreneurs. Plus in my opinion, Marimed levers one of the brightest and well-rounded leadership teams in the marijuana industry.

Medmen Enterprises (MMNFF)

Marijuana retail outfit Medmen Enterprises (OTCMKTS:MMNFF) suddenly became one of the best stocks to buy in botany around mid-October. Within a matter of days, MMNFF stock skyrocketed over 60%. But like most over-the-counter affairs, Medmen gave up its profits just as quickly.

Since its peak closing price, MMNFF stock has dropped a humbling 53%. I get that most investors will balk at such volatility. However, for the speculator, I sense serious growth opportunities for Medmen.

The company has established itself as a retailer of premium cannabis products. Yet many investors may not appreciate that Medmen is a vertically integrated organization. From its upstream production operation down to extraction, branding and distribution, Medmen essentially controls its supply chain. This is a “farm-to-bong” business at its finest.

As Medmen CEO Adam Bierman stated recently, this structure affords the company generous margin-expansion possibilities. Further, the aforementioned high-profile deals only help validate smaller players like MMNFF stock.

Aleafia Health (ALEAF)

Broader and sector weakness has hurt virtually all marijuana stocks. However, the lesser-known names have experienced disproportionate pain. Unfortunately, this is something that Canadian cannabis firm Aleafia Health (OTCMKTS:ALEAF) knows all too well.

But despite its severe market loss over the past two-and-a-half months, ALEAF stock offers a speculative opportunity for risk-takers. For starters, the underlying company features the largest network of referral-only medical cannabis clinics in Canada. Furthermore, their patient base continues to increase as the industry gains social recognition and acceptance.

Management has also invested heavily in cultivation facilities, targeting an annual growing capacity of 98,000 kilograms in 2019. Most importantly, Aleafia has the substance to back up the outlook. In its most recent third-quarter earnings report, the company increased revenue 36%year-over-year.

Diego Pellicer Worldwide (DPWW)

We’ve arrived at the end of our journey regarding marijuana stocks to buy in 2019. In keeping with my loose tradition, I like to throw in an extremely speculative name. And don’t roll your eyes at me: you know you want to know!

The following idea comes from an InvestorPlace reader named Anthony. He asked my opinion regarding Diego Pellicer Worldwide (OTCMKTS:DPWW). My answer to him is the same one I’m giving to you, which is that DPWW stock is extremely risky. Aside from its distressingly low trading volume and market capitalization, Diego Pellicer lacks financial strength to convincingly pull off its licensing and royalties business model.

However, I’m intrigued with its premium branding business. Not that I would know, but Diego Pellicer specializes in high-class cannabis products. As companies like Origin House and Medmen have proven, cannabis users eschew quantity for quality. That could lead to a surprising turnaround for DPWW stock.

Or you can lose every cent that you put in.

As of this writing, Josh Enomoto is long MRMD and ALEAF.

Buffett just went all-in on THIS new asset. Will you?
Buffett could see this new asset run 2,524% in 2018. And he's not the only one... Mark Cuban says "it's the most exciting thing I've ever seen." Mark Zuckerberg threw down $19 billion to get a piece... Bill Gates wagered $26 billion trying to control it...
What is it?
It's not gold, crypto or any mainstream investment. But these mega-billionaires have bet the farm it's about to be the most valuable asset on Earth. Wall Street and the financial media have no clue what's about to happen...And if you act fast, you could earn as much as 2,524% before the year is up.
Click here to find out what it is.

Source: Investor Place